Allarity Therapeutics, Inc.
ALLRHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Allarity Therapeutics, Inc. (ALLR) is listed under Biotechnology. The $19.9M market capitalization puts ALLR squarely in micro-cap range for its industry. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Market Cap
$19.9M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-1.29
EPS (TTM)
$-0.79
EPS (Fwd)
$-0.97
ROE
-157.1%
ROA
-25.3%
Cash
$17.0M
Total Debt
$22.3M
Free CF
-$19.8M
52W Change
-21.6%
Annual Financials
Cash vs Debt
Where ALLR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ALLR finished 11.02% above its 150-day moving average ($1.27) and 13.71% above its 200-day moving average ($1.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALLR overbought or oversold?
At the September 3, 2026 close, ALLR's RSI(14) was 57.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $17.0M in cash, though total debt stands at $22.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$19.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -157.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.56 suggests ALLR is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALLR.